Annual Reports in Medicinal Chemistry
- 1st Edition, Volume 67 - November 1, 2026
- Latest edition
- Editor: Katherine Seley-Radtke
- Language: English
Annual Reports in Medicinal Chemistry, Volume 67 presents authoritative and forward‑looking reviews that capture current advances in medicinal chemistry, with a strong emphas… Read more
Description
Description
Annual Reports in Medicinal Chemistry, Volume 67 presents authoritative and forward‑looking reviews that capture current advances in medicinal chemistry, with a strong emphasis on molecular conjugates, hybrid therapeutics, and precision drug design. Contributions from leading international researchers examine emerging strategies for antiviral, antifungal, and antimicrobial drug development, including small‑molecule conjugates, aptamer–RNA platforms, terpene‑derived hybrids, and intracellular targeting approaches.
The volume highlights how chemical innovation is being leveraged to address drug resistance, emerging viral threats, and unmet clinical needs, while also reflecting broader methodological advances in conjugate design, carrier systems, and structure–activity relationships. As with previous volumes in the series, ARMC 67 serves as both a critical reference and a forward‑looking guide for medicinal chemists in academia and industry.
The volume highlights how chemical innovation is being leveraged to address drug resistance, emerging viral threats, and unmet clinical needs, while also reflecting broader methodological advances in conjugate design, carrier systems, and structure–activity relationships. As with previous volumes in the series, ARMC 67 serves as both a critical reference and a forward‑looking guide for medicinal chemists in academia and industry.
Key features
Key features
- Authoritative reviews by internationally recognised experts in medicinal and pharmaceutical chemistry
- Strong focus on drug conjugates, hybrid molecules, and precision therapeutics
- Coverage of antiviral, antifungal, and antimicrobial strategies addressing emerging and resistant pathogens
- Emphasis on design principles, synthesis, and structure–activity relationships
- Balances fundamental chemical insight with translational and therapeutic relevance
- Essential reference for researchers, graduate students, and professionals in drug discovery and development
Readership
Readership
Ideally suited for chemists engaged in multidisciplinary teams for drug discovery; this includes medicinal chemists and others involved in chemical biology and bio-organic disciplines and computational chemistry
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 67
- Published: November 1, 2026
- Language: English
About the editor
About the editor
KS
Katherine Seley-Radtke
Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to
nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic
emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently
used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as
the Program Director for UMBC’s Chemistry-Biology Interface graduate training program
funded by NIH since 2007. This program promotes hands on cross disciplinary research for
almost 50 PhD students from four departments at UMBC and UMB. She is currently the
Immediate Past President and Secretary-Elect for the International Society of Nucleosides,
Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral
Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections
and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy,
Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Affiliations and expertise
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USA